Literature DB >> 3181278

The effects of chronic carbamazepine treatment of haem biosynthesis in man and rat.

G M McGuire1, G J Macphee, G G Thompson, B K Park, M R Moore, M J Brodie.   

Abstract

The anticonvulsant drug carbamazepine has been reported to produce a condition clinically and biochemically similar to acute intermittent porphyria (AIP). We have determined the effect of chronic carbamazepine treatment on the activities of the enzymes of haem biosynthesis in circulating blood cells and on the urinary excretion of porphyrins and their precursors in 53 epileptic patients receiving monotherapy and in 42 age- and sex-matched controls. In the patients the mean activity of leucocyte 5-aminolaevulinic acid (ALA) synthase, the rate-limiting enzyme of the pathway, was 218% of control values (p less than 0.001) and ALA-dehydratase activity was reduced by 37% (p less than 0.001). Circulating carbamazepine concentrations correlated negatively with ALA dehydratase (rs = -0.45; p less than 0.01). Porphobilinogen deaminase and uroporphyrinogen decarboxylase appeared unaffected by carbamazepine treatment. Significant quantitative increases in the urinary excretion of porphobilinogen and total porphyrins (both p less than 0.05) accompanied the changes in enzyme activity. Similar dose-dependent effects on ALA synthase and ALA dehydratase were shown to occur in rats treated for 5 days with 3 different doses of carbamazepine. These findings further support the porphyrinogenicity of carbamazepine, but the pattern of enzyme alteration differs from that found in AIP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3181278     DOI: 10.1007/bf00558260

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  On the sequence of reactions leading to cytochrome P-450 synthesis-effect of drugs.

Authors:  C Rajamanickam; M R Rao; G Padmanaban
Journal:  J Biol Chem       Date:  1975-03-25       Impact factor: 5.157

2.  Effect of anticonvulsant drugs on serum delta-aminolaevulinic acid levels in non-porphyric subjects.

Authors:  A Gorchein; R Webber; D Burnett; J H Goudie
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

3.  European standardized method for the determination of delta-aminolevulinic acid dehydratase activity in blood.

Authors:  A Berlin; K H Schaller
Journal:  Z Klin Chem Klin Biochem       Date:  1974-08

4.  The optimum use of anticonvulsants.

Authors:  M J Brodie
Journal:  Practitioner       Date:  1985-10

5.  Carbamazepine-induced acute porphyria syndrome.

Authors:  M Doss; H J Schäfer
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

6.  Effect of carbamazepine on haem biosynthesis in man.

Authors:  W G Rapeport; J C Connell; G G Thompson; M R Moore; M J Brodie
Journal:  Eur J Clin Invest       Date:  1984-04       Impact factor: 4.686

Review 7.  Human cytochromes P-450.

Authors:  A R Boobis; D S Davies
Journal:  Xenobiotica       Date:  1984 Jan-Feb       Impact factor: 1.908

8.  Decreased red cell uroporphyrinogen I synthetase activity in intermittent acute porphyria.

Authors:  L J Strand; U A Meyer; B F Felsher; A G Redeker; H S Marver
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

9.  Carbamazepine-induced non-hereditary acute porphyria.

Authors:  A A Yeung Laiwah; W G Rapeport; G G Thompson; G J Macphee; M F Philip; M R Moore; M J Brodie; A Goldberg
Journal:  Lancet       Date:  1983-04-09       Impact factor: 79.321

10.  Familial porphyria cutanea tarda: the pattern of porphyrins formed from porphobilinogen by hemolysates.

Authors:  M A Alleman; J H Wilson; J W van den Berg; A Edixhoven-Bosdijk; L M van Gastel-Quist
Journal:  Clin Chem       Date:  1982-05       Impact factor: 8.327

View more
  1 in total

1.  Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity.

Authors:  A L Herrick; K E McColl; M R Moore; M J Brodie; A R Adamson; A Goldberg
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.